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ChemotherapyIntroduction: Despite considerable research efforts, the process of metastasis formation is still a subject of
intense discussion, and even established models differ considerably in basic details and in the conclu-
sions drawn from them. Mathematical and computational models add a new perspective to the research
as they can quantitatively investigate the processes of metastasis and the effects of treatment. However,
existing models look at only one treatment option at a time.
Methods: We enhanced a previously developed computer model (called CaTSiT) that enables quantitative
comparison of different metastasis formation models with clinical and experimental data, to include the
effects of chemotherapy, external beam radiation, radioimmunotherapy and radioembolization. CaTSiT is
based on a discrete event simulation procedure. The growth of the primary tumor and its metastases is
modeled by a piecewise-deﬁned growth function that describes the growth behavior of the primary
tumor and metastases during various time intervals. The piecewise-deﬁned growth function is composed
of analytical functions describing the growth behavior of the tumor based on characteristics of the tumor,
such as dormancy, or the effects of various therapies. The spreading of malignant cells into the blood is
modeled by intravasation events, which are generated according to a rate function. Further events in the
model describe the behavior of the released malignant cells until the formation of a new metastasis. The
model is published under the GNU General Public License version 3.
Results: To demonstrate the application of the computer model, a case of a patient with a hepatocellular
carcinoma and multiple metastases in the liver was simulated. Besides the untreated case, different treat-
ments were simulated at two time points: one directly after diagnosis of the primary tumor and the other
several months later. Except for early applied radioimmunotherapy, no treatment strategy was able to
eliminate all metastases. These results emphasize the importance of early diagnosis and of proceeding
with treatment even if no clinically detectable metastases are present at the time of diagnosis of the
primary tumor.
Conclusion: CaTSiT could be a valuable tool for quantitative investigation of the process of tumor growth
and metastasis formation, including the effects of various treatment options.
 2015 Elsevier Inc. All rights reserved.1. Introduction
The formation of cancer metastases has been deﬁned as one of
the hallmarks of cancer [1,2]. The clinical importance of metastasis
is highlighted by the fact that more than 90% of cancer patients diebecause of distant metastases and not because of the primary
tumor, which can often be treated locally [3]. Despite its clinical
importance, metastasis formation remains an enigmatic aspect of
cancer biology that is not well enough understood to develop
strategies to prevent their formation [4].
As a complement to experimental research and clinical studies,
mathematical models are valuable tools for investigating the pro-
gress of tumor growth and metastasis and for devising optimal
treatment strategies, such as for chemo- and/or radiation therapy.
Thus, in recent years a variety of mathematical models have been
developed. In 2000 Iwata et al. [5] published a model for the
growth and size distribution of multiple metastatic tumors, which
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number of researchers, including Struckmeier [6], Barbolosi et al.
[7], Devys [8], Haustein and Schumacher [9], Hartung et al. [10]
and Benzekry, who enhanced this model by including the effects
of angiogenesis [11] and dormancy [12]. Another mathematical
approach was developed by Newton et al. [13,14], who calculated
a transition matrix using a stochastic Markov chain model to
describe the growth of primary lung cancer and the spread of
metastases to distant sites.
Further models have been developed that also modeled
chemo- and radiation therapy. The effects of cytotoxic drugs
on tumor growth were modeled by Wheldon [15], Birkhead
[16,17], Usher [18], Panetta [19–21] and Dua [22], for example.
Chemotherapy in combination with antiangiogenic drugs was
modeled by d’Onofrio [23] and Benzekry [24], while de Pillis
examined the combination of chemotherapy with immunother-
apy [25]. Models describing the effects of radiation therapy were
developed by Wang [26], Bernhardt [27,28], Wheldon [29] and
Leder [30], among others. However, in radiation therapy the
use of mathematical models has been limited mainly to calculat-
ing optimal doses [27,28] or obtaining optimal treatment sched-
ules [30,31].
For the analysis of data frommouse models or clinical studies, it
is important to include the effects of different treatment modalities
on the same case, because several treatment modalities are often
combined in practice. In this article a computer model, named
CaTSiT (cancer and treatment simulation tool), is presented that
enables commonly applied treatment options to be simulated.
The original model was published in [32], where it was used to
compare two models of metastatic progression, the linear and par-
allel progression model [33], in a case of a hepatocellular carci-
noma. The comparison of the simulated data with the clinical
data revealed that in this particular case metastasis formation is
an early event and only the ﬁrst metastases seeded from the pri-
mary tumor contribute signiﬁcantly to the tumor burden and thus
cause the patient’s death, if he is left untreated. In [34] the com-
puter model was used to analyze the experimental data of an
HT29 human colon cancer xenograft mouse model. In this context
the computer model was enhanced to model dormancy. The simu-
lation results showed that natural killer cells decelerate the growth
of the primary tumor, kill 80% of the circulating tumor cells that
could have otherwise established a new metastasis and hamper
the establishment and proliferation of the malignant cells in dis-
tant tissue, possibly because of an induction of dormancy in dis-
seminated tumor cells.
In the work presented here the computer model was further
enhanced to model different treatment modalities. Besides the
already implemented complete resection of the primary tumor,
the computer model was now enhanced to model partial resection
and two other commonly applied treatments: chemotherapy and
external beam radiation. Furthermore, two specialized treatments
were added to the computer model: radioimmunotherapy and
radioembolization. In this process the original computer model
was slightly modiﬁed by introducing a piecewise-deﬁned growth
function to facilitate the model and its implementation.
As a demonstration the application of the enhanced computer
model is represented in the results section on the data of one
patient with hepatocellular carcinoma und multiple metastases
in the liver.
Owing to the structure of the computer model and the software,
it is easy to extend CaTSiT to include further new ﬁndings about
metastatic progression and novel treatments in the future. CaTSiT
is available as open source software under the GNU General
Public License version 3. To our knowledge no existing software
package can provide a similar wide range of functionality.2. Methods
2.1. Compartments and events
The basic structure of the computer model was ﬁrst described
in [32] and [35]: It is developed as a building kit [32] that provides
different kinds of building blocks, from which various simulation
setups can be assembled [30,33]. The two main types of building
blocks are compartments and events. A compartment describes a
physical entity that can contain malignant cells; it can be, for
example, the primary tumor, the bloodstream or a metastasis
[32]. An event describes what occurs in a compartment at a speciﬁc
time. In contrast to [32] and [35], events now can have either local
or global effects: local events inﬂuence only one compartment,
whereas global events can affect more than one compartment.
Global events are mostly used to describe therapies such as radia-
tion therapy. Local events are further subdivided into events that
inﬂuence the whole compartment, such as dormancy or resection
of the primary tumor, and events that affect tumor progression,
such as cell division, apoptosis and cell transfer (e.g. intravasation
and extravasation).
Compartments can be modeled either discrete or continuous
[32]. In a continuous compartment, all internal processes are mod-
eled by continuous mathematical functions. The growth of the
compartment size is described by a growth function and the spread
of malignant cells by a colonization rate, which depends on the size
of the compartment and therefore on its growth function. The
growth function and colonization rate can be parameterized indi-
vidually for different compartments, for instance the primary
tumor and different kind of metastases. Larger compartments, such
as the primary tumor and metastases, are usually modeled as con-
tinuous compartments [32].
In a discrete compartment, all internal processes are modeled
with discrete tumor progression events. The increase or decrease
in the number of malignant cells in a discrete compartment is
modeled by simulating each cell division, apoptosis or transloca-
tion into a different compartment. One can think of a discrete com-
partment as a bucket, which cells can be placed into or removed
from. For each discrete compartment a set of possible event types
can be deﬁned, and associated with each event is a probability of
occurrence (see Fig. 1). Discrete compartments are mostly used
to model the bloodstream [32,35].
With these building blocks, various simulation setups can be
constructed to investigate different scenarios of metastatic pro-
gression and treatment strategies. A sample setup involving an
untreated hepatocellular carcinoma with metastases in the liver
and the lung is shown in Fig. 1.
2.2. Modeling tumor growth using a continuous compartment
In a continuous compartment that models the primary tumor or
a metastasis, the growth function x(t) represents the number of
cells in the tumor at time t and is the solution of
dx
dt
¼ gðxÞ; xð0Þ ¼ N0; ð1Þ
where the parameter N0 is the number of cells at time t = 0. When
modeling tumor growth in a human patient, N0 is taken to be 1,
because it is assumed that the primary tumor or a metastasis starts
as a single malignant cell [5,36–38]. When modeling experimental
data, such as data from a mouse model, N0 could be the number
of cells injected into the mouse, for instance.
Different functions can be chosen for the growth rate g(x), such
as linear, exponential or power laws. Most tumors exhibit a
Gompertzian growth rate, which is given by
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Fig. 1. Sample simulation setup for a hepatocellular carcinoma with metastases in the liver and the lung. In this sample simulation setup, the primary tumor is located in the
liver and spreads metastases within the liver and into the lungs. The primary tumor and the metastases are modeled as continuous compartments and the bloodstream is
modeled as a discrete compartment. The primary tumor and the liver metastases grow with the same growth function xLiver(t). Intravasation events (blue solid arrows),
whereby a single malignant cell enters the bloodstream, are generated according to the colonization rate bLiver(x). Lung metastases grow according to the growth function
xLung(t) and do not spread malignant cells into the blood. The possible events that can occur in the bloodstream are listed below the bloodstream along with their associated
probabilities. Most cells in the bloodstream die, and only few can create a new metastasis in either the liver or the lung (red dashed arrows). The probabilities of the events
were chosen arbitrarily for demonstration and do not claim to reﬂect biological reality in the patient. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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x
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where a is the growth rate constant and b represents the maximum
size of the tumor [5]. Taking Eq. (2) as the growth rate g(x) in Eq. (1),
integrating the resulting equation over x and applying the boundary
condition stated in Eq. (1), the number of cells in the tumor at time t
is given by
xðtÞ ¼ b b
N0
 eat
ð3Þ
See Fig. S1-A In The Supplementary Material for the graph of
this function. Other growth functions, arising from linear and
exponential growth rates can be found in Table S1 in the
Supplementary Material.2.3. Modeling tumor spread from continuous compartments
In a continuous compartment the primary tumor and its metas-
tases spread single malignant cells at a colonization rate [5] which
is given by the following function of the tumor size:
bðxÞ ¼ mxd ð4Þ
The parameter m is the colonization coefﬁcient, and d is the
fractal dimension of blood vessel inﬁltration into the tumor; hence,
d describes how well the tumor is supplied with blood. A value of 1
for d signiﬁes that the tumor is completely supplied with blood
while a value of 2/3 indicates that the tumor is only superﬁcially
supplied with blood. To compute the time of the next intravasation
event, the colonization rate is numerically integrated over time,
using Eq. (3) for the number of cells in the tumor, until the integral
reaches the value f. Since it seems not realistic, that the time
between two intravasation events is a ﬁxed value, f is computedfor each single intravasation event randomly in the interval
between 0 and 2 using the Mersenne Twister [39] random number
generator [35].2.4. Modeling dormancy and late dormancy
Metastases can stay dormant for a certain length of time before
they start to grow according to their growth function. To model ini-
tial dormancy of a new metastasis, upon its creation (from a single
cell) its state is set to dormant. In contrast to [34] the growth func-
tion is replaced by a constant function returning the value 1 (see
Fig. S1-B in the Supplementary Material). In this phase no tumor
progression events can be executed or created for this compart-
ment. At the end of the dormancy phase, the state of the compart-
ment is reset and the compartment starts to grow according to the
growth function in Eq. (1). Since it is unlikely that all metastases
remain dormant for the identical time span the length of the dor-
mancy phase is computed randomly for each metastasis using a
random number generator. The distribution of these random val-
ues can be parameterized as either normal distribution with mean
and standard deviation or uniform distribution with an interval
[34]. This parametrization makes it possible to evaluate the effects
of different models of dormancy.
To model late dormancy, the tumor ﬁrst grows according to the
growth function in Eq. (1) until it reaches a certain size ds. The
tumor is then switched to a dormant state, where similar to initial
dormancy the growth function is replaced by a constant function
returning the tumor’s size at the start of the late dormancy phase
(see Fig. S1-C in the Supplementary Material). After the end of
the late dormancy phase, the tumor resumes growing according
to the growth function. In contrast to [34], the accrued offset is
not incorporated by an additional time parameter but by assigning
a new start size N0 = ds to the growth function (see Fig. 2B). Since it
is unlikely that all metastases switch into late dormancy having
the identical number of cells, the start size of the late dormancy
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Fig. 2. Example of a piecewise-deﬁned growth function for the primary tumor and one metastasis. Graphs of growth over time (left) and details of the piecewise-deﬁned
growth functions (right) for a primary tumor (A) and one metastasis (B). (A) The primary tumor is created at the global simulation time 0 and starts growing from a single cell
(N0 = 1) according to a Gompertzian function. On days 500, 550 and 600 chemotherapy is applied to the whole simulated system, during which the current growth function is
replaced by a modiﬁed chemotherapy growth function (xc(t)). On day 750 external beam radiotherapy is applied to the primary tumor, followed by the resection on day 850.
(B) The metastasis is created at global simulation time 100. Similar to the primary tumor, it is created from a single cell (N0 = 1) and grows with a Gompertzian growth rate.
After reaching a size ds = 503 cells, it switches to a dormant state for 200 days. Afterward, the metastasis continues growing according to the initial Gompertzian growth
function but with an updated value of N0 = ds. At the global time points 500, 550 and 600 the metastasis is affected by the chemotherapy. Afterward, the metastasis continues
growing unimpeded. The valid time t for each component function of the piecewise-deﬁned growth function is obtained by subtracting the start time tstart of the currently
valid function from the global time tglobal.
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that can either be normal or uniform [34]. The time-span of the late
dormancy phase is parameterized similarly to that of initial
dormancy.2.5. Modeling therapies
Besides the progression of the primary tumor and its metas-
tases, three of the most commonly applied treatments (resection
of the primary tumor, chemotherapy and external beam radiother-
apy) as well as two more specialized treatments (radioim-
munotherapy and radioembolization) were implemented.2.5.1. Resection of the primary tumor
In an ideal treatment the primary tumor is removed completely
during the resection. In these cases, in a discrete compartment,
resection is modeled by setting the number of cells in the primary
tumor compartment to zero. All cell progression events assigned to
the primary tumor that have not yet been executed at the time of
the resection are deleted from the event list. In a continuous com-
partment, the growth function is replaced by a constant function
returning the value 0 for the number of cells (see Fig. S1-D in the
Supplementary Material). Consequently, the colonization rate will
also become zero, and no more intravasation events will be created
that originate from the primary tumor.
However, complete resection of the primary tumor may not
always be possible. In this case the number of the remaining cells
is computed via a parameterizable remnant fraction. If the primarytumor is modeled as a discrete compartment then the number of
cells is reset to the number of remaining cells. In contrast to com-
plete resection, only a part of the cell progression events that have
not been executed up to the time of the resection are deleted from
the event list according to the remnant fraction. E.g., if 10 cell divi-
sion events of the primary tumor were present in the event list
before the resection and 90% of the cells in the primary tumor were
removed during the resection, then 9 of those cell division events
will be deleted from the event list to account for the decreased
number of cells.
In a continuous compartment, the growth function is replaced
by a modiﬁed version of the original growth function, with the ini-
tial size N0 set to the number of remaining cells.
2.5.2. Chemotherapy
Simulation of chemotherapy is currently available only for con-
tinuous compartments in our computer model. It is modeled by a
modiﬁed growth function xc(t), which is the solution of
dx
dt
¼ gðxÞ  flcðtÞx; xcðtcÞ ¼ Nc ð5Þ
Here g(x) is the growth rate of the tumor, just as in Eq. (1) [15].
The parameter f is used for cycle-speciﬁc chemotherapy [40] and
describes the fraction of cells that are in a cell-cycle phase affected
by the chemotherapy; if the chemotherapy is not cycle-speciﬁc and
thus affects all cells similarly regardless of their cell-cycle state, f is
assigned a value of 1. The parameter l describes the drug sensitiv-
ity of the cells and therefore the effectiveness of the chemotherapy,
and c(t) models the drug concentration in the tumor. In this work
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c = ln(2)/T1/2 [25], where T1/2 denotes the half-life of the drug, was
assumed, so that
cðtÞ ¼ ect ð6Þ
The parameter Nc in Eq. (5) is the number of cells at time tc, the
start time of the chemotherapy cycle.
Upon substituting Eq. (2) for the growth rate g(x) and Eq. (6) for
the drug concentration in Eq. (5) and then solving, the following
modiﬁed growth function xc(t) is obtained:
xcðtÞ ¼ e
fl eatectð Þ
ac
 
b
b
N0
 eat
ð7Þ
See Fig. S1-E in the Supplementary Material for the graph of this
function.
If the compartment is in a dormant state when chemotherapy is
applied, the treatment has no immediate effect. Instead, after the
end of the dormancy phase a delayed version of the growth func-
tion under chemotherapy is applied, in which the drug concentra-
tion is decreased by an amount dependent on the time span
between the chemotherapy and the end of the dormancy phase.
This growth function for delayed chemotherapy, as well as further
chemotherapy growth functions for linear and exponential growth
rates, can be found in Table S1 in the Supplementary Material.
2.5.3. External beam radiation therapy
Each application of external beam radiation therapy (EBRT, or
teletherapy) to the primary tumor is modeled as a single incident
in time, after which the number of surviving cells, ns, is computed
according to the linear quadratic model
ns ¼ nbeaDbD2 ð8Þ
where nb is the number of cells in the tumor before treatment and D
is the radiation dose administered to the tumor during the treat-
ment session. The parameters a and b are tissue constants that
describe the radiosensitivity of the cells being radiated. For exam-
ple, rapidly proliferating tissues, such as mucosa, are much more
radiosensitive and will respond to considerably lower doses than
slowly proliferating tissues, such as bone tissue, which may sustain
higher doses of radiation before they are affected. Simply put, a can
be regarded as the probability, per absorbed dose, of creating a
lethal double-strand break in the DNA that leads to cell death
[41], whereas b can be considered as the probability of inducing
two single-strand breaks in short succession, resulting in a lethal
double-strand break [41].
After application of EBRT to a discrete compartment, the num-
ber of tumor cells is set to the number of surviving tumor cells
ns. Similar to the partial resection of the primary tumor, cell pro-
gression events assigned to the primary tumor that have not been
executed up to the time of the therapy are partially deleted from
the event list according to the survival rate ns/n0.
In a continuous compartment, after EBRT the growth function is
replaced by a modiﬁed version of the original growth function,
with the initial size N0 set to the number of surviving cells ns
(see Fig. 2A and Fig. S1-F in the Supplementary Material). If the
compartment is in a dormant state while radiation therapy is
applied, the constant function during dormancy and the initial con-
dition of the subsequent growth function are updated to the num-
ber of surviving cells ns.
2.5.4. Radionuclide therapy
In addition to standard EBRT, two more specialized therapies
from the ﬁeld of nuclear medicine were implemented in the com-
puter model.2.5.4.1. Radioimmunotherapy. In radioimmunotherapy the radionu-
clide is combined with an antibody that binds to a tumor-
associated antigen to deliver a lethal dose of radiation directly
to the tumor cells [42,43]. In this way, a higher dose can be
delivered to the tumor while the effects on normal tissue are
minimized. In contrast to EBRT, small and as-yet-undetected
metastases can be treated with radioimmunotherapy as well.
However, this is an idealized situation. Recent studies [44,45] have
revealed that in solid tumors, only a very small proportion of the
antibodies can inﬁltrate the tumor and thus deliver the radiation
activity to the tumor cells.
The number of surviving tumor cells, ns, is computed similarly
to EBRT, using Eq. (8). Because the radionuclide is brought directly
into the body and then spreads to the targets, the dose D that is
ﬁnally administered to the single tumors depends on properties
of the applied radionuclide as well as on the administered activity.
It is computed using the following formula derived from the
Medical Internal Radiation Dose (MIRD) Schema [46,47]:
D ¼ AtTeE
mt lnð2Þ ð9Þ
The detailed derivation can be found in the supplementary
material. The parameter mt represents the mass of the tumor, E
the average energy of the radionuclide per disintegration and At
the effective activity in the tumor. It is assumed that the radiation
is absorbed instantly and fades from the system exponentially at a
rate depending on the effective half-life Te, which is a combination
of biological half-life (Tb) and physical half-life (Tp):
Te ¼ Tb TpTb þ Tp ð10Þ
Radioimmunotherapy is modeled as a global event. For each
compartment, i.e. the primary tumor and all metastases, the num-
ber of surviving cells ns is computed as described above with Eqs.
(8)–(10). For this purpose, the effective activity At in each compart-
ment is obtained by distributing the administered activity to the
individual tumors in proportion to their size and applying a clear-
ance fraction, which describes the proportion of the administered
activity that does not contribute to the therapy because it is not
delivered into the individual tumor. After application of therapy,
the number of cells is reset or the growth function updated, respec-
tively, for discrete or continuous compartments, similar to EBRT.2.5.4.2. Radioembolization. Radioembolization, or selective internal
radiation therapy (SIRT), is a therapy speciﬁc for hepatocellular
carcinoma and local metastases within the liver. It is primarily
used when the tumor is non-resectable [48]. The radionuclide
(usually Yttrium 90) is injected into the tumor through the hepatic
artery and delivered via small glass microspheres that then
become trapped in the capillary vessels of the tumor. In this way
the tumor can be irradiated from the inside while the toxicity to
normal liver tissue is minimized [48,49].
Given that the microspheres are brought directly into the blood
vessels of the tumor by the radiologist, only those tumors that are
detectable and connected to a blood supply can be treated. Thus,
very small and not-yet-detected metastases are not affected by this
kind of treatment.
The mean absorbed dose depends on properties of the applied
radionuclide and the administered activity and is computed in
the same way as in radioimmunotherapy, except that, because
the glass microspheres remain in the tissue, the biological
half-life is ignored. Furthermore, only compartments that exceed
a certain size, xmin, are treated. The size xmin can be speciﬁed as
either a diameter or a volume. If a diameter is speciﬁed, the com-
puter model assumes the tumor to be a sphere and computes its
A. Bethge et al. / Journal of Biomedical Informatics 57 (2015) 74–87 79volume accordingly. The number of cells is then computed by
assuming that a tumor with a volume of 1 mm3 contains 106 cells
[50].
In any of the treatments, if the number of cells x(t) falls below
the value 1, the tumor is regarded as extinguished. Hence, as in
the resection simulation, the growth rate is replaced by a constant
function that returns the value 0, all associated events are removed
from the event list and the colonization rate is set to zero.
2.6. Piecewise-deﬁned growth function
As detailed above, different functions are used to describe the
growth of a continuous compartment, the effects of various thera-
pies, and certain characteristics of the tumor, such as dormancy.
Thus, over its entire lifespan in the simulation, the growth of a con-
tinuous compartment can be described by more than one function.
The universal growth function of a continuous compartment is a
piecewise-deﬁned function composed of different continuous
functions that describe the growth behavior of the compartment
during different time periods (see Fig. 2). This piecewise-deﬁned
growth function is implemented as a list in the computer model,
and different functions can be added to the list at various points
in time. These time points are always referenced with respect to
the global time of the current simulation. Hence, the start time
of the ﬁrst component function of the piecewise-deﬁned growth
function is always the creation time of the corresponding compart-
ment, e.g. day 0 for the primary tumor or day 100 for the ﬁrst
metastasis (see Fig. 2). In this way it is easy to obtain the correct
time value for evaluating the currently valid function by taking
the current global time and subtracting the start time of the cur-
rent function.
An example of a piecewise-deﬁned growth function for the pri-
mary tumor and one metastasis is shown in Fig. 2: The primary
tumor is created at the global simulation time 0. It starts as a single
cell (N0 = 1) and grows unimpeded according to a Gompertzian
function until day 500. On days 500, 550 and 600 chemotherapy
is applied to the whole simulated system. At these time points
the initial growth function is replaced by a modiﬁed chemotherapy
growth function that describes the effect of the chemotherapy on
the compartment. On day 750 external beam radiotherapy is
applied to the primary tumor. The number of surviving cells (ns)
is computed according to Eq. (8), and the chemotherapy growth
function is replaced by the initial Gompertzian growth function
with an updated value of N0. Eventually the primary tumor is
resected at day 850. At this time point the growth function is
replaced by a constant function returning the value 0. At global
simulation time 100, the ﬁrst metastasis is created from a single
cell (N0 = 1) and starts growing with a Gompertzian growth rate
(Fig. 2B). When the metastasis reaches a size of 503 cells, it
switches to a dormant state for 200 days. Hence, between the glo-
bal time points 200 and 400, the non-existent growth is modeled
by a constant function that returns the size of the tumor at the
start of the dormancy phase (ds = 503). After the dormancy phase,
the metastasis continues growing according to the initial growth
function but with an updated value of N0. Because chemotherapy
is a systemic therapy, the metastasis is also affected by the
chemotherapy cycles at the global time points 500, 550 and 600.
Similar to the primary tumor, the initial growth function is
replaced by a modiﬁed chemotherapy growth function. The subse-
quent treatments at time points 750 and 850 were applied only to
the primary tumor and have no effect on the metastasis. Hence, the
metastasis continues growing unimpeded after the third
chemotherapy cycle.
As displayed in Fig. 2A the progression of the piecewise-deﬁned
growth function does not have to be continuous (resection of the
primary tumor) or differentiable at every point. Since only theintegral is used to compute the time of new events, these charac-
teristics are insigniﬁcant.
For every continuous compartment in the simulation, its
piecewise-deﬁned growth function is generated individually upon
creation of the compartment. Therefore, the progression of the
piecewise-deﬁned growth function for each compartment is com-
puted independently in advance, taking into account all parame-
terized characteristics and treatments. An exception is the
simulation of radioimmunotherapy. For this treatment, the mean
absorbed dose and thus the number of surviving cells cannot be
computed in advance independently of other compartments
because, as explained above, the effective activity is distributed
to the individual tumors according to their relative size, so that
the total mass of the primary tumor and all metastases is needed.
Although it is possible to compute in advance the number of cells
in all existing tumors, the same cannot be done for tumors that are
yet to be created in the time period between the creation of the
current tumor compartment and the application of radioim-
munotherapy. Thus, in this case the piecewise-deﬁned growth
function is updated at the time of radioimmunotherapy by the cor-
responding event, and then the progression of the
piecewise-deﬁned growth function is recalculated starting from
this time point.
2.7. Simulation procedure
Simulation setups are conﬁgured in the XML (Extensible
Markup Language) format. An XML Schema Deﬁnition (XSD)
describes the structure of the conﬁguration ﬁle. In this ﬁle, the
building blocks (e.g. the primary tumor, bloodstream and metas-
tases) and their properties (e.g. growth function, colonization rate
and cell progression events) are parameterized. Treatments to be
applied are also deﬁned and parameterized in this ﬁle.
CaTSiT parses the conﬁguration ﬁle and creates all the neces-
sary compartments with their associated properties, as well as all
events that can already be determined from the conﬁguration, such
as treatments or the start and stop of a (late) dormancy phase.
All events are stored in an event list and are executed in
sequence according to the global time points at which they occur.
The simulation starts with the creation and execution of the ﬁrst
tumor progression event. When an event is executed, the compart-
ment is changed according to the event type. For example, during a
cell division event the number of cells in the compartment is
increased by one, whereas after a resection event the number of
cells is set to zero or the number of cells remaining in the tissue,
respectively. If the actual event is a tumor progression event, then
a new event is created according to the deﬁned set of event types
for the compartment and the associated probabilities. The time of
the newly created event is computed from a mean time function
and a distribution which is used to model variance in the compu-
tation of the time value. Both, the mean time function and the dis-
tribution can be parameterized separately for each tumor
progression event in the event set. In this way new events are con-
tinually created and executed. The simulation stops when a
pre-speciﬁed time span has been covered.
During the simulation, the current state of the system is regu-
larly saved in a spreadsheet. The following values are saved: time
in minutes and in days, number of cells in the primary tumor,
number of cells in the bloodstream, number of metastases, number
of cells in all metastases, and a size histogram of all the metastases.
If metastases occur in more than one host organ, the simulation
can be conﬁgured to save information about the number of metas-
tases, cells and the size histogram of metastases individually for
each host organ.
Usually, each simulation setup is computed about 100 times.
After completion of all simulation runs for a given setup, the mean
Fig. 3. Simulation procedure. Simulation setups, including the properties of all compartments and treatments, are conﬁgured in a XML (Extensible Markup Language) ﬁle
(conﬁguration.xml). Technical information such as the duration the simulation shall cover and the interval in which the current state of the simulated system shall be saved
are parametrized in a separate XML ﬁle (technical.xml). The CaTSiT software (black frame) parses both ﬁles, creates all necessary compartments and events and starts the
simulation by creating the ﬁrst tumor progression event. Events are stored by time in an event list. One by one, the next event is retrieved from the event list and executed
until the parametrized time span was covered. According to its parametrization an event inﬂuences one or more compartments. If it is a tumor progression event, than a new
event is created after the execution to describe what happens next in the corresponding compartment. The current status of the system, including current time, size of the
primary tumor, number of metastases and a size histogram of all metastases is saved periodically in a buffer which is written in a spreadsheet ﬁle at the end of the simulation.
If parametrized in the conﬁguration ﬁle, separate result ﬁles can be created for each organ. To create variance, a single simulation setup is simulated several times. Afterward,
mean and standard deviation are computed, which than can be used to analyze and visualize the simulation results.
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Table 1
Parameter values used in the sample simulation setups.
Parameter Name Value Source
Tumor growth
a Growth rate constant 0.00286 day1 Iwata [5]
b Maximum size of tumor 7.3  1010 cells
m Colonization coefﬁcient 5.3  108 (cell day)1
d Fractal dimension of blood vessels 0.663
Chemotherapy (7 cycles in an interval of 14 days [25])
f Fraction of tumor cells in S-phase 0.26 Pourgholami [51]
l Fraction of tumor cells killed by chemotherapy 0.9 Morris [52]
c Drug decay rate 0.92 day1 Derived from de Pillis [25] and Chan [53]
External beam radiation therapy
a Radiosensitivity 0.35 Gy1 Bernhardt [28]
b Radiosensitivity 0.023 Gy1 derived from Tai [54]
D Administered dose 36 Gy in daily 2 Gy fractions, 5 times a week Zeng [55], Huang [56], Cupino [57]
Radioimmunotherapy with 131I (Iodine 131) labeled antibodies
A0 Administered activity 0.93 GBq Zeng [55]
Clearance fraction 0.9 Heine [44,45]
E Average energy per disintegration 0.1818 MeV/(Bq s) Eckerman [58]
Tp Physical half-life of radionuclide 192.48 h Eckerman [58]
Tb Biological half-life of radionuclide 66  24 h Kramer [59]
Radioembolisation with 90Y (Yttrium 90)
A0 Injected activity 0.5 GBq Kennedy [48]
E Average energy per disintegration 0.9337 MeV/(Bq s)
Tp Physical half-life of radionuclide 64.2 h
xmin Minimum size for treatment 65.45 mm3 (diameter 5 mm) Derived from Iwata [5]
A. Bethge et al. / Journal of Biomedical Informatics 57 (2015) 74–87 81and standard deviation of the results are computed. This simula-
tion procedure is also displayed in Fig. 3.
CaTSiT is publicly available as open source software under GNU
General Public License version 3 (GPL-3.0), and can be obtained
from http://bioinformatics.fh-stralsund.de/catsit/. On this website,
binary and source ﬁles of the software are presented together with
a detailed description of the software and the XML Schema, sample
conﬁguration ﬁles, and instructions for installing and using CaTSiT.3. Results
To demonstrate the broad possibilities of the computer model,
various simulation setups for the case of a patient with hepatocel-
lular carcinoma and multiple metastases in the liver were simu-
lated. The data of this patient was published by Iwata et al. [5].
As in the simulation setup shown in Fig. 1, the primary tumor
and metastases were modeled as continuous compartments and
the bloodstream was modeled as a discrete compartment, but in
this case the primary tumor spreads into the liver only. To save
on computation time, the colonization rate was parameterized to
include only those cells that survive in the bloodstream and even-
tually create a metastasis. Hence, in this simulation setup the set of
possible events that can occur in the bloodstream includes only
one event: the creation of a new liver metastasis. Dormancy was
not included in the simulations since there was no evidence that
dormancy occurred in this patient. As already demonstrated in
[35] and [32], this simulation setup can reproduce the clinical data
of this one particular patient.
This simulation setup for the untreated case was now used as a
basis to simulate different treatments for this patient, such as
resection of the primary tumor, EBRT applied to the primary tumor,
cycle-speciﬁc chemotherapy, cycle-nonspeciﬁc chemotherapy,
radioimmunotherapy with Iodine 131-labeled antibodies,
radioembolization with Yttrium 90, and a combination of primary
tumor resection and cycle-nonspeciﬁc chemotherapy.
Although chemotherapy is not a standard treatment regime in
hepatocellular carcinoma, we still included this treatment optionin the simulations, to demonstrate the capabilities of the computer
model, since it can easily be parametrized for other types of cancer
where chemotherapy is a standard treatment option. Treatments
were applied on day 700, which is about a month after the initial
diagnosis of the primary tumor, and on day 1500, to study the dif-
ferences between tumors diagnosed and treated early and those
diagnosed and treated late. Treatments were simulated for the case
where metastases themselves can metastasize and for the case
where only the primary tumor can spread metastases. The param-
eters for the various simulation setups were taken from the litera-
ture and are listed in Table 1.
Altogether, 30 different simulation setups were simulated. The
results of the simulations are shown in Figs. 4 and 5, which show
the mean values of 100 simulation runs for each single simulation
setup. On day 700, the primary tumor had a size of approximately
2.5  109 cells, and about 10 metastases with a standard deviation
of r = 2 metastases were present. In contrast, on day 1500 the pri-
mary tumor had a size of 5.2  1010 cells, and the number of
metastases present was 1117 (r = 83), in the case where metas-
tases themselves can metastasize, or 330 (r = 10), in the case
where only the primary tumor can metastasize.
If treatment commences early, resection of the primary tumor
leads to temporary (Fig. 4A) or complete (Fig. 5A) stagnation in
the number of metastases. In contrast, if treatment commences
late, resection of the primary tumor has almost no effect on the
number of metastases if metastases themselves can metastasize
(Fig. 4A). If metastases cannot metastasize, the number of metas-
tases stagnates after resection of the primary tumor (Fig. 5A).
However, in both cases the total tumor burden is barely affected,
because at day 1500 the metastases already constitute the majority
of the tumor burden (Figs. 4A and 5A). The results in Figs. 4 and 5
show the ideal case in which all tumor cells of the primary tumor
could be removed during resection. Simulations with a remnant
fraction of 0.1% were also performed and are shown in Fig. S3 in
the Supplemental Materials. Especially, in those simulation setups
where metastases are not able to metastasize and the treatment
started early at day 700 the remnant has a major impact on the
number of metastases. In contrast to complete resection as shown
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Fig. 4. Simulation results for different treatments for the simulation setups where metastases are able to metastasize. The graphs A–G display the number of metastases
(dashed lines, right y-axis) and the total tumor burden (solid lines, left y-axis) over time, for the untreated course (black lines in panels A–G) and seven simulated treatments:
(A) resection of the primary tumor (PT), (B) EBRT of the primary tumor, (C) cycle-speciﬁc chemotherapy, (D) cycle-nonspeciﬁc chemotherapy, (E) radioimmunotherapy, (F)
radioembolization, and (G) a combination of primary tumor resection and cycle-nonspeciﬁc chemotherapy. Treatments were started once shortly after diagnosis of the
primary tumor on day 700 (red lines) and once on day 1500 (blue lines). In the panels A and B the untreated course is masked by the simulation results of the treatment
started at day 1500. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
82 A. Bethge et al. / Journal of Biomedical Informatics 57 (2015) 74–87in Fig. 5B the number of metastases starts rising again after some
time after the remnant of the primary tumor was able to recover
and regrow to a size at which the recurrence was able to spread
metastases again (see Fig. S3B).
Although EBRT cannot completely eliminate the primary tumor,
it reduces its volume considerably. Hence, if treatment is applied
early, the number of metastases stagnates for some time after
treatment before starting to rise again (Figs. 4B and 5B). In the latetreatment case, similar to resection of the primary tumor, EBRT has
almost no impact on the total tumor burden.
Cycle-speciﬁc chemotherapy has little direct effect on the num-
ber of metastases. Because only 26% of the cells are in the cell-cycle
phase that responds to the treatment, only very small metastases
established during or shortly before the individual chemotherapy
cycles are eliminated. Cycle-nonspeciﬁc chemotherapy eradicates
slightly more metastases than does cycle-speciﬁc chemotherapy.
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Fig. 5. Simulation results for different treatments for the simulation setups where only the primary tumor is able to spread metastases. The graphs A–G display the number of
metastases (dashed lines, right y-axis) and the total tumor burden (solid lines, left y-axis) over time, for the untreated course (black lines in panels A–G) and seven simulated
treatments: (A) resection of the primary tumor (PT), (B) EBRT of the primary tumor, (C) cycle-speciﬁc chemotherapy, (D) cycle-nonspeciﬁc chemotherapy, (E)
radioimmunotherapy, (F) radioembolization, and (G) a combination of primary tumor resection and cycle-nonspeciﬁc chemotherapy. Treatments were started shortly after
diagnosis of the primary tumor on day 700 (red lines) and once on day 1500 (blue lines). In the panels A and B the untreated course is masked by the simulation results of the
treatment started at day 1500. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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number of metastases indirectly, by reducing the number of cells
in the primary tumor and the surviving metastases and thus slow-
ing down the creation of new metastases (Figs. 4C–D and 5C–D).
Radioembolization can completely eradicate the primary
tumor, but if treatment occurs early, the existing metastases are
still too small to be detected and are therefore not affected bythe treatment. Hence, in the early treatment case, radioemboliza-
tion yields results similar to those for resection of the primary
tumor (Figs. 4F and 5F). On day 1500, about 102 metastases
(r = 7) (metastases do metastasize) or 95 metastases (r = 6)
(metastases do not metastasize) have a diameter of 5 mm or
greater and are potentially detectable clinically. They are therefore
included in the treatment and are also completely eliminated like
84 A. Bethge et al. / Journal of Biomedical Informatics 57 (2015) 74–87the primary tumor. Thus, the total tumor burden can be decreased
considerably in contrast to resection of the primary tumor or EBRT
of the primary tumor (Figs. 4F and 5F).
If radioimmunotherapy is applied early while the primary
tumor and metastases are still relatively small, it has the potential
to completely eliminate the primary tumor and all metastases
(Figs. 4E and 5E). If applied later in the progression of the
disease, radioimmunotherapy can still reduce the number of cells
considerably, although not as effectively as radioembolization
(Figs. 4E–F and 5E–F), and it cannot eliminate the primary tumor.
Because radioimmunotherapy also affects small metastases, this
treatment can eliminate more metastases than radioembolization.
However, because the primary tumor is not eradicated, the number
of metastases soon starts rising again. Radioimmunotherapy has
also been simulated with a varying clearance fraction of 0 (the
whole administered activity is delivered to the tumor cells) and
0.95 (only 5% of the administered activity is delivered to the tumor
cells). The results for early applied therapy do not differ from
the results with an applied clearance fraction of 0.9 as shown
in Figs. 4 and 5: the primary tumor and all metastases were
completely eliminated. If radioimmunotherapy was applied late,
different clearance fractions lead to different results in the number
of metastases and total tumor burden (see Fig. S2 in the
Supplementary Material). The results show that even in late
applied therapy the same amount of activity still has the potential
to eliminate the primary tumor and all metastases if the complete
administered activity could be delivered to the site of the tumors.
Combination therapy involving primary tumor resection and
cycle-nonspeciﬁc chemotherapy shows the most promising results
if applied early (Figs. 4G and 5G). The combination therapy can
reduce the tumor burden to some 10,000 cells, but as with the
other types of therapy, the tumor burden starts rising again if no
further treatments are applied. Again, these simulation results
show the ideal case for the primary tumor resection. Simulation
results for a remnant fraction of 0.1% are shown in Fig. S3 in the
Supplemental Materials.
These results illustrate, in a quantitative manner, the impor-
tance of early diagnosis and the continuation of a treatment strat-
egy even if no metastases are detectable after the ﬁrst treatment
cycle.4. Discussion
CaTSiT is constructed using compartments and events as build-
ing blocks to describe the behavior of a tumor progression and
metastasis system. This approach makes this tool very ﬂexible
and allows researchers to create, simulate and analyze a wide vari-
ety of setups including those ones relevant to cancer therapy.
Different growth and spreading behaviors can be assigned to the
primary tumor and metastases – and even to different types of
metastases (e.g. lung, liver or bone metastases). Thus, different
models of tumor progression and metastatic behavior (such as
early or late metastasis, linear or parallel progression) can be
examined with one computer model, which facilitates the compar-
ison of those different models.
In contrast to hitherto published models, such as for example
Iwata [5] or Benzekry [12], CaTSiT thereby uses a discrete event
simulation approach, which inter alia allows simulating variance.
Hence, instead of providing just one single result, multiple simula-
tion runs of the same simulation setup result in a range of varying
outcomes as it would also appear in real biological systems.
Furthermore, CaTSiT can also simulate tumor growth and meta-
static progression under the inﬂuence of three main types of cancer
therapy – primary tumor resection, chemotherapy and radiation
therapy – and all these treatments can be combined in a singlesimulation setup. To our knowledge, no existing mathematical or
computational model can accommodate this extensive and realis-
tic kind of analysis. Existing models address either radiation ther-
apy [26,29,30,41] or chemotherapy [17,20–22,24,60–62] (alone or
in combination with primary tumor resection, immunotherapy or
antiangiogenic drugs), but not both.
Since the characteristics of the different compartments, events
and treatment regimens are deﬁned in a specially developed
XML ﬁle, CaTSiT can be used without the necessity of profound
programming or mathematical skills, which makes it suitable for
a wide range of applications in an easy way. This easy access is
supported by the XSD which can be used to validate the conﬁgura-
tion ﬁles while editing.
The building-block structure also enables straightforward
extension and enhancement of the computer model. New ﬁndings
and further therapies can easily be incorporated into the software.
For instance, the implementation of remnants left in the tissue dur-
ing the resection of the primary tumor took less than four hours. Of
course, the time to implement new characteristics or treatments
depends strongly on their complexity but this example nicely
demonstrates how promptly the model and the CaTSiT software
can be extended.
4.1. Modeling tumor dormancy
In his model, Benzekry [12] used a dynamic maximal tumor size
(see Eq. (2)): the carrying capacity. He modeled dormancy by intro-
ducing extra parameters to describe the production, efﬁcacy and
elimination of angiogenesis inhibitors that inﬂuence the carrying
capacity of the tumor and therefore allow or limit its growth.
CaTSiT includes dormancy by replacing the current growth func-
tion with a constant function. This simpliﬁed approach has the
advantage that no new mathematical terms and parameters have
to be introduced, apart from parameterization of the starting size
and duration of the dormancy phase.
4.2. Parametrization
Obviously, the results of the simulation depend strongly on the
parametrization of the growth and spreading behavior of the pri-
mary tumor and the metastases and the parametrization of the
treatments. While the dosage and frequency of drugs or radiation
therapy is mostly predeﬁned by treatment regimens and therefore
won’t vary strongly between patients in similar stages of the dis-
ease, the initial parameter of tumor growth and spreading behavior
can vary greatly from one patient to another. Variation in only one
parameter may lead to very different courses in the development
of metastases and the total tumor burden. For example, as already
demonstrated in [32], applying a higher growth rate to the metas-
tases as to the primary tumor (+50% and +100%) for this one
patient resulted in a signiﬁcantly higher number of metastases,
in the simulation setups where metastases were able to
metastasize.
Concerning therapies, not only dosage and frequency but also
tissue related parameter such as the proportion of cells in cycle,
radiosensitivity of tumor cells or the ability to deliver drugs to
the tumor cells inﬂuence the efﬁciency of the treatment.
Exemplarily, for radioimmunotherapy, variation was simulated
for the clearance fraction (0, 0.9 and 0.95) and the radio sensitivity
parameters a and b (±20%). In both examples the simulation results
do not differ for the case that treatment is started early at day 700:
the primary tumor and all metastases are still completely elimi-
nated. At day 1500 the clearance fraction has a great impact on
the results (see Fig. S2). As already stated in the results section
the same amount of administered activity lead to the complete
elimination of the primary tumor and all metastases if the value
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value from 0.9 to 0.95 resulted in a clearly recognizable higher
number of metastases and total tumor burden (see Fig. S2).
Increasing or decreasing the radiosensitivity parameters a and b
by 20% also resulted in a recognizable lower or higher number of
metastases and total tumor burden (see Fig. S4) as the radiosensi-
tivity parameters inﬂuenced the number of cells which got killed
during radiation therapy. However, in comparison, a and b have
less impact on the simulation results than the clearance fraction.
4.3. Limitations of the computer model
As shown in [32] and [34], CaTSiT can simulate an untreated
course of tumor progression and metastasis that is in good quanti-
tative agreement with both clinical [32] and experimental [34]
data. However, because it uses a coarse-grained approach, it does
not incorporate every detail. For instance, it does not differentiate
between resistant and nonresistant cells, as Birkhead [16,17] did in
his model for chemotherapy. Birkhead introduced ﬁve parameters
to describe the rates at which cells switch between cycling and
resting phases, divide, are killed, and gain resistance to cytotoxic
drugs. In contrast, CaTSiT uses only three parameters to describe
the effects of cytotoxic drugs; this facilitates the parameterization,
but as a consequence the simulated treatments represent ideal
courses and do not include any resistances that may arise during
chemotherapy.
CaTSiT does not consider the inﬂuence of radiation therapy on
normal tissue. Hence, treatment strategies that seem promising
in the simulation results may not be feasible in vivo owing to
potential increased damage to normal tissue.
At present, EBRT in our model is only available for the primary
tumor. In the computer model the tumor and metastases are not
given a speciﬁc location, except for ‘‘somewhere in this organ’’,
so currently it is not possible to simulate the application of treat-
ment to only a few metastases in a speciﬁed area of an organ.
During simulation of radioembolization treatment, the same
activity is applied to each treated tumor regardless of its size; it
is currently not possible to parameterize different activities for dif-
ferent tumors. Hence, depending on the number of treated metas-
tases, the applied activity may exceed the maximum level
tolerated in the affected organ.
The different treatments can be combined at will in CaTSiT,
with one exception: radiation therapy cannot be applied directly
after chemotherapy. During chemotherapy a completely different
growth function is used that describes the inﬂuence of the
chemotherapeutic drug on each tumor over time. Applying radia-
tion therapy immediately after chemotherapy would require set-
ting up a new model that can describe the effects of both
therapies combined. Hence, for the time being, in the simulation
radiation therapy can only be applied after the chemotherapy drug
has worn off, resetting the growth function to its initial form in the
process.
The implementation of the chemotherapy and radiation therapy
has not yet been validated with clinical or experimental data and
will need further examination by applying it to experimental data
from xenograft models and clinical data from many more patients.
Since this is beyond the focus of this manuscript, this approach will
be modeled in subsequent work. Until now, usage of CaTSiT has
been limited to analyzing data from one untreated patient [32]
and from a xenograft experiment where no treatments were
applied [34]. Nevertheless, in these settings the computer model
has been able to provide some important insights.
CaTSiT has considerable strengths. Since it is possible to run
many different simulation setups under the same computer model,
CaTSiT can be used in a broad range of ﬁelds, enabling us to analyze
data in a more sophisticated way. Characteristics and patterns canbe discovered that classical statistical analyses cannot reveal, as
shown for instance in [34]. CaTSiT can also be used to compare dif-
ferent models of cancer growth, as shown in [32], to estimate the
number of metastases not yet detectable, and to predict the impact
of various treatments on the primary tumor and metastases, in
order to plan optimal treatment schedules. Furthermore, it can
easily be extended to include further characteristics and new
treatments.
In current research we thoroughly validate the computer model
by applying it to the experimental data of different cancer cell
lines, where the mice were treated either with chemotherapy, radi-
ation therapy or a combination of chemo and radiation therapy.
Furthermore, since it is quite common in chemotherapy and
radiation therapy for a certain amount of tumor cells to be resis-
tant and/or develop resistances during the course of treatment, it
is planned in the near future to extend the computer model to
model these resistances as well.
5. Conclusion
CaTSiT provides an important and easy-to-use tool for analyzing
data and investigating the progress of tumor growth and metasta-
sis formation in combination with different treatment options.
Future plans include application of CaTSiT to a larger collection
of clinical and experimental data. By publishing CaTSiT, we want
to give access of our modeling tool to the research community to
use it to do similar modeling for research and to further enhance
its modeling capacities.
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